leadf
logo-loader
viewThird Pole Therapeutics

Third Pole Therapeutics anticipates FDA clearance end of 2021 to treat newborn respiratory failure

Third Pole Therapeutics CEO Bill Athenson sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The company, based in Waltham, Massachusetts, is developing transformative cardio-pulmonary therapies such as its FDA-approved pulmonary vasodilator to treat hypoxic respiratory failure in newborns.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Trident Royalties is 'all about diversification unlike majority of its peers'

Proactive analyst Ryan Long focuses on Trident Royalties (LON:TRR) a newly AIM-listed diversified mining royalty and streaming business. The company aims to provide investors with exposure to a broad range of development and cash-generating mining assets across the base metal, precious metal,...

50 minutes ago

2 min read